{"id":28382,"date":"2024-05-14T14:24:37","date_gmt":"2024-05-14T19:24:37","guid":{"rendered":"https:\/\/myeloma.ca\/?p=28382"},"modified":"2024-05-14T14:32:07","modified_gmt":"2024-05-14T19:32:07","slug":"un-moment-historique-lodac-vote-a-lunanimite-en-faveur-de-lutilisation-de-la-mesure-de-la-mrm-comme-critere-devaluation-precoce-dans-les-essais-cliniques-sur-le-m","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2024\/05\/14\/un-moment-historique-lodac-vote-a-lunanimite-en-faveur-de-lutilisation-de-la-mesure-de-la-mrm-comme-critere-devaluation-precoce-dans-les-essais-cliniques-sur-le-m\/","title":{"rendered":"Un moment historique : l\u2019ODAC vote \u00e0 l\u2019unanimit\u00e9 en faveur de l\u2019utilisation de la mesure de la MRM comme crit\u00e8re d\u2019\u00e9valuation pr\u00e9coce dans les essais cliniques sur le my\u00e9lome pour ouvrir la voie \u00e0 l\u2019approbation acc\u00e9l\u00e9r\u00e9e de nouveaux traitements\u00a0"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">L\u2019<em>Oncologic Drugs Advisory Committee<\/em> (ODAC) de la <em>Food and Drug Administration<\/em> (FDA) des \u00c9tats-Unis a recommand\u00e9 l\u2019utilisation de la mesure de la maladie r\u00e9siduelle minimale (MRM) comme crit\u00e8re d\u2019\u00e9valuation pr\u00e9coce dans les essais cliniques sur le my\u00e9lome. Si cette recommandation est adopt\u00e9e par la FDA, elle pourrait ouvrir la voie \u00e0 l\u2019approbation acc\u00e9l\u00e9r\u00e9e de nouveaux traitements.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.myeloma.org\/blog\/dr-duries\/odac-unanimously-in-favor-mrd-testing-early-endpoint-myeloma\" target=\"_blank\" rel=\"noopener\" title=\"\">Lire la suite (en anglais)&#8230; <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019Oncologic Drugs Advisory Committee (ODAC) de la Food and Drug Administration (FDA) des \u00c9tats-Unis a recommand\u00e9 l\u2019utilisation de la mesure de la maladie r\u00e9siduelle minimale (MRM) comme crit\u00e8re d\u2019\u00e9valuation pr\u00e9coce dans les essais cliniques sur le my\u00e9lome. Si cette recommandation est adopt\u00e9e par la FDA, elle pourrait ouvrir la voie \u00e0 l\u2019approbation acc\u00e9l\u00e9r\u00e9e de nouveaux [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[88,53],"tags":[],"class_list":["post-28382","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-evenement"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/28382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=28382"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/28382\/revisions"}],"predecessor-version":[{"id":28383,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/28382\/revisions\/28383"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=28382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=28382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=28382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}